Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  16.00 0.2% 8,141.00 8,150.00 8,153.00 8,262.00 8,144.00 8,159.00 1,709,559 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 19,468.2 2,864.2 178.5 46.0 126,114

Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose

17/06/2021 11:14pm

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Jun 2021 to Sep 2021

Click Here for more Astrazeneca Charts.
   By Kim Mackrael 

OTTAWA--A Canadian vaccine panel said Thursday that people who received a first dose of AstraZeneca PLC's vaccine against Covid-19 should get a different vaccine for their second dose.

Canada's national advisory panel on immunization said earlier this month that authorized Covid-19 vaccines could be mixed, and noted some people might prefer to get a messenger RNA vaccine for their second shot. The panel has previously said mRNA vaccines, such as the ones produced by Pfizer Inc. in partnership with BioNTech SE, as well as Moderna Inc., are preferable to viral vector vaccines, such as those developed by AstraZeneca and Johnson & Johnson.

On Thursday, it changed its advice to recommend against the use of AstraZeneca's vaccine in most cases.

"An mRNA vaccine should now be offered as the second dose for individuals who received a first dose" of AstraZeneca's vaccine, said Dr. Howard Njoo, Canada's deputy chief public health officer. People who are getting their first vaccine dose should also be offered an mRNA vaccine unless they have a contraindication or none of those vaccines are available, he said.

Dr. Njoo said the advisory panel's advice is based on emerging evidence that shows a potentially better immune response from a mixed vaccine schedule, and concerns about blood clotting associated with the AstraZeneca vaccine. Another factor the advisory panel considered is the increased availability of mRNA vaccines in Canada, he said.

The panel's recommendations aren't binding, but tend to be followed by provinces in Canada, which are responsible for delivering health care.

After a sluggish start earlier in the year, Canada has sharply increased its administration of Covid-19 vaccines in recent months. Nearly 66% of the population had received at least one dose of a Covid-19 vaccine as of June 16, although just 15% of the population is fully vaccinated.


Write to Kim Mackrael at kim.mackrael@wsj.com


(END) Dow Jones Newswires

June 17, 2021 18:05 ET (22:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210917 05:13:34